Last $15.65 USD
Change Today +0.35 / 2.29%
Volume 238.7K
FLML On Other Exchanges
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

flamel technologies-sp adr (FLML) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/22/14 - $19.50
52 Week Low
01/14/15 - $9.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

flamel technologies-sp adr (FLML) Related Businessweek News

No Related Businessweek News Found

flamel technologies-sp adr (FLML) Details

Flamel Technologies SA, a specialty pharmaceutical company, develops and commercializes pharmaceutical products based on its proprietary polymer based technology. The company owns and develops drug delivery platforms, such as Micropump that allows generating and marketing modified and/or controlled release of solid and oral dosage formulations of drugs; and LiquiTime, which develops modified/controlled release of liquid formulations for patients having issues swallowing tablets or capsules. Its drug delivery platforms also comprise Trigger Lock that develops tamper-resistant modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, which develops extended/modified release of injectable dosage formulations of drugs. The company’s lead products include Bloxiverz, a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Coreg CR, a non-selective antagonist of Beta 1, Beta 2 adrenergic receptors and a selective antagonist of Alpha 1 adrenergic receptors used for the treatment of moderate to severe heart failure and left ventricular dysfunction following myocardial infarction. It has collaborations with various pharmaceutical and biotechnology companies, including GlaxoSmithKline plc. Flamel Technologies SA was founded in 1990 and is headquartered in Vénissieux, France.

Founded in 1990

flamel technologies-sp adr (FLML) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

flamel technologies-sp adr (FLML) Key Developments

Flamel Technologies SA(NasdaqGM:FLML) added to NASDAQ Biotechnology Index

Flamel Technologies SA will be added to the NASDAQ Biotechnology Index.

Flamel Technologies Announces Positive Results of Second Clinical Trial with Micropump Sodium Oxybate

Flamel Technologies announced that its second clinical study in healthy volunteers using its proprietary Micropump technology applied to sodium oxybate has achieved the objective of one single dose before bedtime for patients suffering from narcolepsy, confirming the results of a previous, first-in-man, study. The current dosing regimen for the standard of care, Xyrem, in the United States is two equal, divided doses: the first dose at bedtime and the second dose 2.5 to 4 hours later. The elimination of the second dose for narcolepsy patients would not only provide more convenience, but may improve the benefit sodium oxybate provides as there will be no disruption to nighttime sleep. The potential for additional benefits, including improved safety, will be studied. The trial was designed as a 2-arm study with 12 patients in each arm evaluating two different formulations of Micropump sodium oxybate at a nightly dose of 4.5g, 6g and 7.5g. Each subject consumed a standard meal two hours prior to dosing. Subjects were instructed to maintain a consistent meal time and dosing schedule throughout the study. One subject dropped out of the study prior to the completion of the 7.5g dosing portion for reasons unrelated to drug. The data for both formulations at the 4.5g and 6g doses were consistent with the data seen in the previous study which showed: Onset of action similar to Xyrem, Cmax lower than Xyrem, Mean blood concentration (ug/ml) at hours 7 and 8 similar to Xyrem. The data at the 7.5g dose for both formulations were consistent with expectations given the data generated at the lower doses. While both formulations were successful, Flamel has chosen to move forward with the optimal formulation. To date, Micropump sodium oxybate has been tested in 40 healthy subjects across three doses among three different formulations with no safety or tolerability issues.

Flamel Technologies SA Reports Unaudited Consolidated Cash Flow Results for the Nine Months Ended September 30, 2014

Flamel Technologies SA reported unaudited consolidated cash flow results for the nine months ended September 30, 2014. For the period, the company reported net cash used in operating activities of $4,306,000 against $13,658,000 a year ago. Purchases of property and equipment were $1,404,000 against $766,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FLML:US $15.65 USD +0.35

FLML Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $15.00 USD +0.285
Durect Corp $1.05 USD -0.02
Onxeo €6.28 EUR +0.05
Veloxis Pharmaceuticals A/S kr1.12 DKK +0.01
XenoPort Inc $6.85 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation FLML Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.9x
Price/Book 15.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FLAMEL TECHNOLOGIES-SP ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at